Cancer Research and Treatment

Original Articles

CNS cancer

Choosing Wisely between Radiotherapy Dose-Fractionation Schedules: The Molecular Graded Prognostic Assessment for Elderly Glioblastoma Patients: Hye In Lee, Jina Kim, In Ah Kim, Joo Ho Lee, Jaeho Cho, Rifaquat Rahman, Geoffrey Fell, Chan Woo Wee, Hong In Yoon; Cancer Res Treat. 2025;57(2):378-386. Published online September 11, 2024; DOI: https://doi.org/10.4143/crt.2024.680

Abstract PDF Supplementary Material PubReader ePub: Purpose
This study aimed to develop a graded prognostic assessment (GPA) model integrating genomic characteristics for elderly patients with glioblastoma (eGBM), and to compare the efficacy of different radiotherapy schedules.
Materials and Methods
This multi-institutional retrospective study included patients aged ≥ 65 years who underwent surgical resection followed by radiotherapy with or without temozolomide (TMZ) for newly diagnosed eGBM. Based on the significant factors identified in the multivariate analysis for overall survival (OS), the molecular GPA for eGBM (eGBM-molGPA) was established.
Results
A total of 334 and 239 patients who underwent conventionally fractionated radiotherapy (CFRT) and hypofractionated radiotherapy (HFRT) were included, respectively, with 86% of patients receiving TMZ-based chemoradiation. With a median follow-up of 17.4 months (range, 3.3 to 149.9 months), the median OS was 18.7 months for CFRT+TMZ group, 15.1 months for HFRT+TMZ group, and 10.4 months for radiotherapy alone group (CFRT+TMZ vs. HFRT+TMZ: hazard ratio [HR], 1.52; p < 0.001 and CFRT+TMZ vs. radiotherapy alone: HR, 2.52; p < 0.001). In a combined analysis with the NOA-08 and Nordic trials, CFRT+TMZ group exhibited the highest survival rates among all treatment groups. The eGBM-molGPA, which integrated four clinical and three molecular parameters, stratified patients into low-, intermediate-, and high-risk groups. CFRT+TMZ significantly improved OS compared to HFRT+TMZ or radiotherapy alone in the low-risk (p=0.023) and intermediate-risk groups (p < 0.001). However, in the high-risk group, there was no significant difference in OS between treatment options (p=0.770).
Conclusion
CFRT+TMZ may be more effective than HFRT+TMZ or radiotherapy alone for selected eGBM patients. The novel eGBM-molGPA model can guide treatment selection for this patient population.

1,231 View
111 Download

Gastrointestinal cancer

Clinical Significance of Combining Preoperative and Postoperative Albumin-Bilirubin Score in Colorectal Cancer: Doyoun Kim, Jae-Hoon Lee, Eun-Suk Cho, Su-Jin Shin, Hye Sun Lee, Hwa-Hee Koh, Kang Young Lee, Jeonghyun Kang; Cancer Res Treat. 2023;55(4):1261-1269. Published online April 17, 2023; DOI: https://doi.org/10.4143/crt.2022.1444

Abstract PDF Supplementary Material PubReader ePub

Purpose
Albumin-bilirubin (ALBI) score is a well-known prognostic factor for various diseases, including colorectal cancer (CRC). However, little is known about the significance of postoperative ALBI score changes in patients with CRC.
Materials and Methods
A total of 723 patients who underwent surgery were enrolled. Preoperative ALBI (ALBI-pre) and postoperative ALBI (ALBI-post) scores were divided into low and high score groups. ALBI-trend was defined as a combination of four groups comprising the low and high ALBI-pre and ALBI-post score groups. Kaplan-Meier survival curves were used to compare the overall survival (OS) between the different ALBI groups. The Cox proportional hazards model was used to examine the independent relevant factors of OS. Stratification performance was compared between the different ALBI groupings using Harrell’s concordance index (C-index).
Results
ALBI-pre, ALBI-post, and ALBI-trend score groups were significant prognostic factors of OS in the univariable analysis. However, multivariable analysis showed that ALBI-trend was an independent prognostic factor while ALBI-pre and ALBI-post were not. The C-index of ALBI-trend (0.622; 95% confidence interval [CI], 0.587 to 0.655) was higher than that of ALBI-pre (0.589; 95% CI, 0.557 to 0.621; bootstrap mean difference, 0.033; 95% CI, 0.013 to 0.057) and ALBI-post (0.575; 95% CI, 0.545 to 0.605; bootstrap mean difference, 0.047; 95% CI, 0.024 to 0.074).
Conclusion
Combining ALBI-pre and ALBI-post scores is an independent prognostic factor of OS and shows superior predictive power compared to ALBI-pre or ALBI-post alone in patients with CRC.

Citations

Citations to this article as recorded by

Comparing laboratory toxicity of selective intra-arterial radionuclide therapy for primary and metastatic liver tumors: resin versus glass microspheres
Başak Soydaş-Turan, M. Fani Bozkurt, Gonca Eldem, Bora Peynircioglu, Omer Ugur, Bilge Volkan-Salanci
Annals of Nuclear Medicine.2025; 39(4): 373. CrossRef
Improvement of Hypoalbuminemia and Hepatic Reserve after Stent Placement for Postsurgical Portal Vein Stenosis
Naoya Kinota, Daisuke Abo, Ryo Morita, Koji Yamasaki, Takaaki Fujii, Daisuke Kato, Tasuku Kimura, Yusuke Sakuhara, Kazufumi Okada, Isao Yokota, Tatsuya Orimo, Tatsuhiko Kakisaka, Toru Nakamura, Satoshi Hirano, Kazuyuki Minowa, Kohsuke Kudo
Journal of Vascular and Interventional Radiology.2025; 36(4): 616. CrossRef
Gastrointestinal tumors of the small bowel: prognostic roles of tumor stage and inflammatory markers
Mehmet Torun, Sevil Özkan, Deniz Kol Özbay, Erkan Özkan
Anatolian Current Medical Journal.2025; 7(2): 164. CrossRef
Predictive value of preoperative serum cytokeratin 19 fragment antigen 21-1(CYFRA 21-1) in surgical resection for colorectal cancer: A retrospective study
Shuyuan Gu, Shihui Chen, Yuan Chai, Chao Qu, Xuejun Sun, Junhui Yu
Current Problems in Surgery.2025; : 101791. CrossRef
Sex-Specific Associations of Total Bilirubin, ALBI, and PALBI with Lung Cancer Risk: Interactions with Smoking and Alcohol
Jong Won Shin, Nguyen Thien Minh, Sun Ha Jee
Healthcare.2025; 13(11): 1321. CrossRef
Assessment of the albumin-bilirubin score in breast cancer patients with liver metastasis after surgery
Li Chen, Chunlei Tan, Qingwen Li, Zhibo Ma, Meng Wu, Xiaosheng Tan, Tiangen Wu, Jinwen Liu, Jing Wang
Heliyon.2023; 9(11): e21772. CrossRef

3,724 View
182 Download
3 Web of Science
6 Crossref

Gynecologic cancer

Genomic and Transcriptomic Characterization Revealed the High Sensitivity of Targeted Therapy and Immunotherapy in a Subset of Endometrial Stromal Sarcoma: Nan Kang, Yinli Zhang, Shichao Guo, Ran Chen, Fangzhou Kong, Shuchun Wang, Mingming Yuan, Rongrong Chen, Danhua Shen, Jianliu Wang; Cancer Res Treat. 2023;55(3):978-991. Published online February 2, 2023; DOI: https://doi.org/10.4143/crt.2022.1647

Abstract PDF PubReader ePub

Purpose
The unique chromosomal rearrangements of endometrial stromal sarcoma (ESS) make it possible to distinguish high-grade ESS (HGESS) and low-grade ESS (LGESS) from the molecular perspective. Analysis of ESS at the genomic and transcriptomic levels can help us achieve accurate diagnosis of ESS and provide potential therapy options for ESS patients.
Materials and Methods
A total of 36 ESS patients who conducted DNA- and/or RNA-based next-generation sequencing were retrospectively enrolled in this study. The molecular characteristics of ESS at genomic and transcriptomic levels, including mutational spectrum, fusion profiles, gene expression and pathway enrichment analysis and features about immune microenvironment were comprehensively explored.
Results
TP53 and DNMT3A mutations were the most frequent mutations. The classical fusions frequently found in HGESS (ZC3H7B-BCOR and NUTM2B-YWHAE) and LGESS (JAZF1-SUZ12) were detected in our cohort. CCND1 was significantly up-regulated in HGESS, while the expression of GPER1 and PGR encoding estrogen receptor (ER) and progesterone receptor (PR) did not differ significantly between HGESS and LGESS. Actionable mutations enriched in homologous recombination repair, cell cycle, and phosphoinositide 3-kinase/AKT/mammalian target of rapamycin pathways were detected in 60% of HGESS patients. Genes with up-regulated expression in HGESS were significantly enriched in five immune-related pathways. Most HGESS patients (85.7%) had positive predictors of immunotherapy efficacy. Moreover, immune microenvironment analysis showed that HGESS had relatively high immune infiltration. The degree of immune infiltration in HGESS patients with ZC3H7B-BCOR fusion was relatively higher than that of those with NUTM2B-YWHAE fusion.
Conclusion
This study investigated the molecular characteristics of ESS patients at the genomic and transcriptomic levels and revealed the potentially high sensitivity of targeted therapy and immunotherapy in a subset of HGESS with specific molecular features, providing a basis for guiding decision-making of treatment and the design of future clinical trials on precision therapy.

Citations

Citations to this article as recorded by

Integrated Transcriptomic Landscape and Deep Learning Based Survival Prediction in Uterine Sarcomas
Yaolin Song, Guangqi Li, Zhenqi Zhang, Yinbo Liu, Huiqing Jia, Chao Zhang, Jigang Wang, Yanjiao Hu, Fengyun Hao, Xianglan Liu, Yunxia Xie, Ding Ma, Ganghua Li, Zaixian Tai, Xiaoming Xing
Cancer Research and Treatment.2025; 57(1): 250. CrossRef
Molecular Insights in Endometrial Stromal Sarcomas: Exploring New Targets for Novel Therapeutic Approaches
Alice Costa, Annalisa Astolfi, Livia Gozzellino, Margherita Nannini, Gianandrea Pasquinelli, Maria Abbondanza Pantaleo
Biomolecules.2025; 15(2): 265. CrossRef
Risk factors, survival analysis, and nomograms for high-grade endometrial stromal sarcoma patients with distant metastasis: a population-based study (2010–2019)
Cheng Wang, Dongni Liang, Wei Kuang, Huanxin Sun, Yuling Kou, Wei Wang, Jing Zeng
Frontiers in Oncology.2025;[Epub] CrossRef
Genomic and T cell repertoire biomarkers associated with malignant mesothelioma survival
Muwen Nie, Zhao Sun, Ningning Li, Liangrui Zhou, Shuchun Wang, Mingming Yuan, Rongrong Chen, Lin Zhao, Ji Li, Chunmei Bai
Thoracic Cancer.2024; 15(19): 1502. CrossRef
Single-cell RNA-seq reveals FGF12 as a prognostic biomarker in low-grade endometrial stromal sarcoma
Yu Miao, Meng Dong, Qiyin Zhou, Julia Thiel, Na Li, Ying Cai, Dan Yuan, Haitao Wang, Su-Han Jin, Hua Yang, Jinjing Wang, Benjamin Frey, Udo S. Gaipl, Hu Ma, Jian-Guo Zhou
Frontiers in Immunology.2024;[Epub] CrossRef
High-Grade Endometrial Mesenchymal Sarcoma: Current Status and Future Trends
Zhang Lushuang, Zhao Liubiqi
Clinical Journal of Obstetrics and Gynecology.2023; 6(3): 132. CrossRef

4,785 View
193 Download
5 Web of Science
6 Crossref

Gastrointestinal cancer

Evaluation and Comparison of Predictive Value of Tumor Regression Grades according to Mandard and Becker in Locally Advanced Gastric Adenocarcinoma: Yilin Tong, Yanmei Zhu, Yan Zhao, Zexing Shan, Dong Liu, Jianjun Zhang; Cancer Res Treat. 2021;53(1):112-122. Published online August 10, 2020; DOI: https://doi.org/10.4143/crt.2020.516

Abstract PDF Supplementary Material PubReader ePub

Purpose
Tumor regression grade (TRG) has been widely used in gastrointestinal carcinoma to assess pathological responses to neoadjuvant chemotherapy (NCT). There are various standards without a consensus, and it is still unclear which kind of system has better predictive value. This study aims to investigate and compare the predictive ability of the Mandard and Becker TRGs in patients with locally advanced gastric cancer.
Materials and Methods
A total of 290 patients with locally advanced gastric adenocarcinoma who underwent NCT and curative surgery were studied. Survival analysis for overall survival (OS) and disease-free survival (DFS) were based on the Kaplan-Meier method and Cox proportional hazards method. Predictive values of TRGs and models were assessed by time-dependent receiver operating characteristic (ROC) curve, the area under the ROC curve (AUC), nomogram, and calibration curve.
Results
In multivariable analysis, the Mandard TRG was associated with OS (hazard ratio [HR], 1.806; p=0.026) and DFS (HR, 1.792; p=0.017). The Becker TRG was also related to OS (HR, 1.880; p=0.014) and DFS (HR, 1.919; p=0.006). The Mandard and Becker TRG AUCs for 5-year survival were 0.72 and 0.71, respectively. The whole models showed an increased predictive value, with AUCs of 0.85 and 0.86, respectively. There was no significant difference between the two TRGs and two models.
Conclusion
TRG was an independent predictor for survival, and there was no significant difference between these two systems.

Citations

Citations to this article as recorded by

CT-Derived Quantitative Image Features Predict Neoadjuvant Treatment Response in Adenocarcinoma of the Gastroesophageal Junction with High Accuracy
Markus Graf, Sebastian Ziegelmayer, Stefan Reischl, Yannick Teumer, Florian T. Gassert, Alexander W. Marka, Philipp Raffler, Jeannine Bachmann, Marcus Makowski, Daniel Reim, Fabian Lohöfer, Egon Burian, Rickmer Braren
Cancers.2025; 17(2): 216. CrossRef
Patterns of Survival and Recurrence in Poor Responders to Neoadjuvant Therapy for Gastric Cancer: A Real-World Multicenter Study
Qing Zhong, Cai-Ming Weng, Mei-Chen Jiang, Yu-Qin Sun, Bao-Long Li, Wei Zhao, Hao-Xiang Zhang, Zhi-Quan Zhang, Yu-Bin Ma, Shi-Chao Wu, Wen Ye, Ju Wu, He Du, Chao-Hui Zheng, Ping Li, Qi-Yue Chen, Chang-Ming Huang, Jian-Wei Xie
Annals of Surgical Oncology.2025;[Epub] CrossRef
Radiomic-based models are able to predict the pathologic response to different neoadjuvant chemotherapy regimens in patients with gastric and gastroesophageal cancer: a cohort study
Annamaria Agnes, Luca Boldrini, Federica Perillo, Huong Elena Tran, Maria Gabriella Brizi, Riccardo Ricci, Jacopo Lenkowicz, Claudio Votta, Alberto Biondi, Riccardo Manfredi, Vincenzo Valentini, Domenico M. D’Ugo, Roberto Persiani
World Journal of Surgical Oncology.2025;[Epub] CrossRef
Microsatellite instability in gastric cancer: An institutional case series analysis in patients treated with neoadjuvant therapy
Laura Lorenzon, Alberto Biondi, Gloria Santoro, Annamaria Agnes, Antonio Laurino, Antonia Strippoli, Riccardo Ricci, Roberto Persiani, Domenico D'Ugo
Clinical Surgical Oncology.2024; 3(1): 100031. CrossRef
The Evolving Landscape of Neoadjuvant Immunotherapy in Gastroesophageal Cancer
Colum Dennehy, Alisha F. Khan, Ali H. Zaidi, Vincent K. Lam
Cancers.2024; 16(2): 286. CrossRef
Evaluating Treatment Response in GEJ Adenocarcinoma
Markus Graf, Joshua Gawlitza, Marcus Makowski, Felix Meurer, Thomas Huber, Sebastian Ziegelmayer
Investigative Radiology.2024; 59(8): 583. CrossRef
Deep learning nomogram for predicting neoadjuvant chemotherapy response in locally advanced gastric cancer patients
Jingjing Zhang, Qiang Zhang, Bo Zhao, Gaofeng Shi
Abdominal Radiology.2024; 49(11): 3780. CrossRef
Intratumoral heterogeneity affects tumor regression and Ki67 proliferation index in perioperatively treated gastric carcinoma
Magnus Kock am Brink, Laura Sophie Dunst, Hans-Michael Behrens, Sandra Krüger, Thomas Becker, Christoph Röcken
British Journal of Cancer.2023; 128(2): 375. CrossRef
Time to Surgery does not Affect Oncologic Outcomes in Locally Advanced Gastric Cancer after Neoadjuvant Chemotherapy: A Meta-Analysis
Zining Liu, Zhening Zhang, Hua Liu, Junbing Chen
Future Oncology.2023; 19(5): 397. CrossRef
Response Evaluation after Neoadjuvant Chemotherapy for Resectable Gastric Cancer
Alina Desiree Sandø, Reidun Fougner, Elin Synnøve Røyset, Hong Yan Dai, Jon Erik Grønbech, Erling Audun Bringeland
Cancers.2023; 15(8): 2318. CrossRef
Profiling complete regression after pre-operative therapy in gastric cancer patients using clinical and pathological data
Alberto Biondi, Laura Lorenzon, Gloria Santoro, Annamaria Agnes, Antonio Laurino, Roberto Persiani, Domenico D'Ugo
European Journal of Surgical Oncology.2023; 49(11): 106969. CrossRef
Concurrent clinical and pathological response predicts favorable prognosis of patients with gastric cancer after neoadjuvant therapy: a real-world study
Chongyuan Sun, Penghui Niu, Xiaojie Zhang, Lulu Zhao, Wanqing Wang, Xiaoyi Luan, Xue Han, Yingtai Chen, Dongbing Zhao
BMC Cancer.2023;[Epub] CrossRef
Sintilimab Plus Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer and Biomarker Exploration
Jiangpeng Wei, Xin Guo, Xisheng Yang, Jinqiang Liu, Qianqian Duan, Yuan Tan, Qin Zhang, Tingting Sun, Chuang Qi, Xiaohua Li, Gang Ji
Future Oncology.2023; 19(36): 2395. CrossRef
Evaluation of dual-energy CT derived radiomics signatures in predicting outcomes in patients with advanced gastric cancer after neoadjuvant chemotherapy
Yong Chen, Fei Yuan, Lingyun Wang, Elsie Li, Zhihan Xu, Michael Wels, Weiwu Yao, Huan Zhang
European Journal of Surgical Oncology.2022; 48(2): 339. CrossRef
MORBIDITY AND SURVIVAL AFTER PERIOPERATIVE CHEMOTHERAPY IN GASTRIC CANCER: A STUDY USING THE BECKER’S CLASSIFICATION AND REGRESSION
Maria Cecília de Aguiar MACHADO, José Pedro Coimbra de Vargas Lobarinhas BARBOSA, Filipa Ferreira de OLIVEIRA, José Adelino Lobarinhas BARBOSA
ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo).2022;[Epub] CrossRef
Validating a nodal regression system for gastric cancer: An ancillary cohort study of the GASTRODOC trial
Luca Saragoni, Leonardo Solaini, Daniele Marrelli, Maria Raffaella Ambrosio, Maria Bencivenga, Anna Tomezzoli, Carlo Milandri, Valentina Terrinazzi, Gian Luca Baiocchi, Carla Baronchelli, Flavia Foca, Giorgio Ercolani, Paolo Morgagni
International Journal of Surgery.2021; 94: 106112. CrossRef
Comparison of tumor regression grading systems for locally advanced gastric adenocarcinoma after neoadjuvant chemotherapy
Zi-Ning Liu, Yin-Kui Wang, Li Zhang, Yong-Ning Jia, Shan Fei, Xiang-Ji Ying, Yan Zhang, Shuang-Xi Li, Yu Sun, Zi-Yu Li, Jia-Fu Ji
World Journal of Gastrointestinal Oncology.2021; 13(12): 2161. CrossRef

7,648 View
148 Download
20 Web of Science
17 Crossref

Risk Factors for Cognitive Impairment in High-Grade Glioma Patients Treated with Postoperative Radiochemotherapy: Qiang Wang, Fengxia Xiao, Fei Qi, Xiaopeng Song, Yonghua Yu; Cancer Res Treat. 2020;52(2):586-593. Published online December 12, 2019; DOI: https://doi.org/10.4143/crt.2019.242

Abstract PDF PubReader ePub

Purpose
Fractionated radiotherapy as well as concomitant and adjuvant chemotherapy such as temozolomide for postoperative high-grade glioma (HGG) patients improves progression-free survival and overall survival. Multiple factors such as chemotherapy, radiotherapy, tumor grade, residual tumor volume, and genetic modifications might play a role in the formation of cognitive impairment. The risk factors of cognitive impairment in postoperative patients with HGG receiving radiotherapy and chemotherapy remains a concern in this population. The purpose of this study was to identify risk factors for cognitive impairment in patients of postoperative HGG.
Materials and Methods
A total of 229 patients with HGG who underwent surgery were analyzed. Cognitive impairment was defined as a decrease of Cognitive Assessment Montreal (MoCA)’s score in at least two cognitive domains or any MoCA’s score of less than 26 points at the time of study compared with baseline level. Multiple potential risk factors including methylated status of the O⁶-methylguanine-DNA methyltransferase (MGMT) promoter, glioma World Health Organization (WHO) grade, residual tumor volume, education, and sex were analyzed. Cox univariate and multivariate regression analysis was used to detect the significant risk factors for cognitive impairment.
Results
At the end of follow-up among the 229 patients, 147 patients (67%) developed cognitive impairment. 82 patients (36%) remained in normal cognitive condition. In multivariate analysis, unmethylated MGMT promoter (hazard ratio [HR], 1.679; 95% confidence interval [CI], 1.212 to 2.326; p=0.002), glioblastoma (HR, 1.550; 95% CI, 1.117 to 2.149; p=0.009), and residual tumor volume > 5.58 cm³ (HR, 1.454; 95% CI, 1.047 to 2.020; p=0.026) were independent risk factors for cognitive impairment.
Conclusion
Methylated status of the MGMT promoter, glioma WHO grade, and residual tumor volume might be risk factors for the cognitive impairment in postoperative patients with HGG.

Citations

Citations to this article as recorded by

The relationship between social participation and cognitive function early after surgery of glioma patients
Yinglian Xiao, Jing Tan, Guo Cheng, Yanhong Deng, Ryota Tamura
PLOS ONE.2025; 20(2): e0319220. CrossRef
Clinical Outcome Assessment Tools for Evaluating the Management of Gliomas
Sachiv Chakravarti, Sneha R. Gupta, Saket Myneni, Mazin Elshareif, James L. Rogers, Chad Caraway, A. Karim Ahmed, Karisa C. Schreck, David O. Kamson, Matthias Holdhoff, Victoria Croog, Kristin J. Redmond, Chetan Bettegowda, Debraj Mukherjee
Cancers.2025; 17(10): 1659. CrossRef
BTK Expression Level Prediction and the High-Grade Glioma Prognosis Using Radiomic Machine Learning Models
Chenggang Jiang, Chen Sun, Xi Wang, Shunchang Ma, Wang Jia, Dainan Zhang
Journal of Imaging Informatics in Medicine.2024; 37(4): 1359. CrossRef
Epigenome-Wide Analysis of DNA Methylation and Optimism in Women and Men
Cuicui Wang, Dawn L. DeMeo, Eric S. Kim, Andres Cardenas, Kelvin C. Fong, Lewina O. Lee, Avron Spiro, Eric A. Whitsel, Steve Horvath, Lifang Hou, Andrea A. Baccarelli, Yun Li, James D. Stewart, JoAnn E. Manson, Francine Grodstein, Laura D. Kubzansky, Joel
Psychosomatic Medicine.2023; 85(1): 89. CrossRef
Factors affecting cognitive functions of patients with high-grade gliomas: a systematic review
Rabeet Tariq, Nowal Hussain, Muhammad Waqas Saeed Baqai
Neurological Sciences.2023; 44(6): 1917. CrossRef
Cognitive functioning in a cohort of high-grade glioma patients
Andreja Cirila Skufca Smrdel, Anja Podlesek, Marija Skoblar Vidmar, Jana Markovic, Jana Jereb, Manja Kuzma Okorn, Uros Smrdel
Radiology and Oncology.2023; 57(2): 201. CrossRef
Cognitive outcomes after multimodal treatment in adult glioma patients: A meta-analysis
Laurien De Roeck, Céline R Gillebert, Robbie C M van Aert, Amber Vanmeenen, Martin Klein, Martin J B Taphoorn, Karin Gehring, Maarten Lambrecht, Charlotte Sleurs
Neuro-Oncology.2023; 25(8): 1395. CrossRef
Factors Associated With Neurocognitive Impairment Following Chemoradiotherapy in Patients With High-Grade Glioma: Results of a Prospective Trial
Prashasti Sharma, Partha Pratim Medhi, Apurba Kumar Kalita, Mouchumee Bhattacharyya, Jyotiman Nath, Gautam Sarma, Yanpothung Yanthan
Brain Tumor Research and Treatment.2023; 11(3): 183. CrossRef
Knockdown of TRIM32 inhibits tumor growth and increases the therapeutic sensitivity to temozolomide in glioma in a p53-dependent and -independent manner
Yu Cai, Wei Ting Gu, Kang Cheng, Pei Feng Jia, Feng Li, Ming Wang, Wei Feng Zhang, Ji Ting Qiu, Zhe Bao Wu, Wei Guo Zhao
Biochemical and Biophysical Research Communications.2021; 550: 134. CrossRef
Sensitivity of the Montreal Cognitive Assessment in screening for cognitive impairment in patients with newly diagnosed high-grade glioma
Monica Ribeiro, Thomas Durand, Martine Roussel, Loïc Feuvret, Julian Jacob, Dimitri Psimaras, Georges Noel, Audrey Keller, Flavie Bompaire, Khê Hoang-Xuan, Marie-Odile Bernier, Olivier Godefroy, Damien Ricard
Journal of Neuro-Oncology.2020; 148(2): 335. CrossRef

7,793 View
173 Download
14 Web of Science
10 Crossref

Type-Specific Viral Load and Physical State of HPV Type 16, 18, and 58 as Diagnostic Biomarkers for High-Grade Squamous Intraepithelial Lesions or Cervical Cancer: Jongseung Kim, Bu Kyung Kim, Dongsoo Jeon, Chae Hyeong Lee, Ju-Won Roh, Joo-Young Kim, Sang-Yoon Park; Cancer Res Treat. 2020;52(2):396-405. Published online August 28, 2019; DOI: https://doi.org/10.4143/crt.2019.152

Abstract PDF Supplementary Material PubReader ePub

Purpose
High rate of false-positive tests is a major obstacle to use human papillomavirus (HPV) detection as a diagnostic tool for high-grade squamous intraepithelial lesions or cervical cancer (HSIL+). We investigated whether type-specific viral load or physical state of HPV 16, 18, and 58 are useful biomarkers for HSIL+.
Materials and Methods
Type-specific viral loads of E6 and E2 genes in cervical cells from 240, 83, and 79 HPV 16–, 18–, and 58–infected women, respectively, were determined using real-time polymerase chain reaction. Viral loads were normalized to cellular DNA (copy/cell). Total and integrated viral loads and physical state were compared between HSIL+ and controls, and diagnostic value was determined using receiver operating characteristic analysis.
Results
Viral loads of HPV 16, 18, and 58 were significantly different in lesions in the same pathologic grade. High type-specific total viral loads were significantly associated with HSIL+ (odds ratio [OR], 14.065, 39.472, and 7.103 for HPV 16, 18, and 58, respectively). High integrated viral load was related to HSIL+ in women with HPV 16 (OR, 8.242), and integrated state was associated with HSIL+ in women with HPV 18 (OR, 9.443). Type-specific total viral load was significantly associated with HSIL+ (area under curve, 0.914, 0.937, and 0.971 for HPV 16, 18, and 58, respectively), indicating an excellent performance in detecting HSIL+.
Conclusion
Type-specific total viral load may be a powerful diagnostic marker for HSIL+ in HPV 16–, 18–, and 58–infected HSIL+ lesions. If demonstrated in all other high-risk HPV types, this method can lead to a paradigm shift in the strategy of equivocal cytologic abnormalities.

Citations

Citations to this article as recorded by

Correlation of different HPV genotype viral loads and cervical lesions: A retrospective analysis of 1585 cases
Yilu Zhou, Jiaxin Liu, Shuai Chen, Xianzhen Xin, Mohan Xiao, Xian Qiang, Lina Zhang
Cancer Cytopathology.2025;[Epub] CrossRef
Analysis of HPV-16 viral load, integration status, and p16 expression in relation to EBV co-infection and cervical lesion severity
Azam Khamseh, Ali Farhadi, Somayeh Jalilvand, Fariba Yarandi, Narges Izadi-Mood, Saied Ghorbani, Hassan Saadati, Elham Shirali, Seyed Mohammad Jazayeri, Jamal Sarvari
Scientific Reports.2025;[Epub] CrossRef
Progress in the Study of Cervical Cancer Screening Methods
祺孙
Advances in Clinical Medicine.2025; 15(03): 1989. CrossRef
Electrochemical Duplex Detection of E2 and E6 Genes of Human Papillomavirus Type 16 and Determination of Physical Status in High‐Risk Cervical Carcinoma
Sinthu Karunaithas, Thanyarat Chaibun, Patutong Chatchawal, Chamras Promptmas, Waranun Buajeeb, Lee Su Yin, Patcharee Jearanaikoon, Benchaporn Lertanantawong
Journal of Medical Virology.2025;[Epub] CrossRef
HPV vaccination status and effectiveness in Korean women with HPV16/18 infection (2010–2021): a retrospective study
Yoo Jin Na, Oeuk Jeong, Jaehyun Seong, JeongGyu Lee, So Young Lee, Sooyoung Hur, Sangmi Ryou
Journal of Gynecologic Oncology.2024;[Epub] CrossRef
Evaluation of human papillomavirus type 16 viral load and genome physical status in Iranian women with cervical disease
Shadi Setayeshi, Ali Hasanzadeh, Yousef Yahyapour, Ahad Alizadeh, Hossein Ghorbani, Fahimeh Nokhostin, Meghdad Bagheri, Farzin Sadeghi
Molecular Biology Reports.2024;[Epub] CrossRef
Biomarkers in the Screening and Management of Cervical Cancer
Pallavi Punhani, Charanjeet Ahluwalia
Journal of Colposcopy and Lower Genital Tract Pathology.2024; 2(1): 6. CrossRef
Prevalence of Carcinogenic Genotypes of HPV-Infected Women in a Ten-Year Period (2014–2023) in Vojvodina, Serbia
Natasa Nikolic, Branka Basica, Mirjana Strbac, Lidija Terzic, Aleksandra Patic, Gordana Kovacevic, Radmila Velicki, Dusan Petrovic, Aljosa Mandic, Vladimir Petrovic
Medicina.2024; 60(6): 922. CrossRef
Increased human papillomavirus viral load is correlated to higher severity of cervical disease and poorer clinical outcome: A systematic review
Seth‐Frerich Fobian, Xionge Mei, Johannes Crezee, Barbara C. Snoek, Renske D. M. Steenbergen, Jiafen Hu, Timo L. M. ten Hagen, Louis Vermeulen, Lukas J. A. Stalpers, Arlene L. Oei
Journal of Medical Virology.2024;[Epub] CrossRef
The Diagnostic Significance of Combined Screening and Human Papillomavirus 16 and 18 Cycle Threshold Values for CIN2+ Cervical Lesions
Xue Bai, Ya-Kun Liu, Ya-Jing Jia, Dao-Juan Li, Nai-Yi Du
International Journal of Women's Health.2024; Volume 16: 1959. CrossRef
Evaluation of Human Papilloma Virus (HPV) Genotyping and Viral Load Determination as Diagnostic Biomarkers of Cervical Cancer Risk
Marianna Martinelli, Chiara Giubbi, Laura Saderi, Rosario Musumeci, Federica Perdoni, Biagio Eugenio Leone, Robert Fruscio, Fabio Landoni, Andrea Piana, Giovanni Sotgiu, Clementina Elvezia Cocuzza
International Journal of Molecular Sciences.2023; 24(2): 1320. CrossRef
Implications of viral infections and oncogenesis in uterine cervical carcinoma etiology and pathogenesis
Daming Chu, Tengteng Liu, Yuan Yao
Frontiers in Microbiology.2023;[Epub] CrossRef
Prevalence and Risk Factors for High-Risk Human Papillomavirus Infection and Cervical Disorders: Baseline Findings From an Human Papillomavirus Cohort Study
Paula Saldaña-Rodríguez, Margarita Bahena-Román, Karina Delgado-Romero, Vicente Madrid-Marina, Kirvis Torres-Poveda
Cancer Control.2023;[Epub] CrossRef
A Review of the Application of Heterostructure Catalysts in Hydrogen Evolution Reaction
Shizhi Dong, Yanshuai Li, Zhilong Zhao, Ruichuan Li, Jiaqi He, Jinpeng Yin, Bing Yan, Xing Zhang
ChemistrySelect.2022;[Epub] CrossRef
The frequency of infection with high-risk human papilloma virus types on the cervix uteri of women of reproductive age
Jovana Prelić, Aleksandra Knežević
Medicinski podmladak.2022; 73(1): 55. CrossRef
Influence of Lacidophilin Vaginal Capsules plus rh-IFN-α2b on Efficacy, Vaginal Microecology, and Safety of Patients with HPV Infection
Yan Sun, Jianqun Xu, Hongya Zhou, Lina You, Yan Zhu, Shoib Baba
Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1. CrossRef
Comparison of cycle threshold values of the Cobas HPV test and viral loads of the BMRT HPV test in cervical cancer screening
Qing Yang, Hui Du, Xinfeng Qu, Wenkui Dai, Liming Gui, Changzhong Li, Chun Wang, Chunlei Guo, Yi Zhang, Lihui Wei, J. L. Belinson, Ruifang Wu
Frontiers in Public Health.2022;[Epub] CrossRef
EGFR Protein Expression Relates with Tumor Histology, Methylation Status of EGFR and HPV16 E6 Viral Load in Oropharyngeal Carcinoma
Yo Suzuki, Yuki Fukumura, Miki Asahina, Mitsuhisa Fujimaki, Shinichi Ohba, Fumihiko Matsumoto, Isao Kurahayashi, Takashi Yao, Katsuhisa Ikeda
Head and Neck Pathology.2021; 15(3): 743. CrossRef
Detection of 14 High-Risk Human Papillomaviruses Using Digital LAMP Assays on a Self-Digitization Chip
Jiasi Wang, Jeannette P. Staheli, Andrew Wu, Jason E. Kreutz, Qiongzheng Hu, Jingang Wang, Thomas Schneider, Bryant S. Fujimoto, Yuling Qin, Gloria S. Yen, Bob Weng, Kara Shibley, Halia Haynes, Rachel L. Winer, Qinghua Feng, Daniel T. Chiu
Analytical Chemistry.2021; 93(6): 3266. CrossRef
Viral load and high prevalence of HR-HPV52 and 58 types in black women from rural communities
Lays Paula Bondi Volpini, Jerusa Araújo Dias, Luciana Bueno de Freitas, Maria Carmen Lopes Ferreira Silva, Angélica Espinosa Miranda, Liliana Cruz Spano
BMC Infectious Diseases.2021;[Epub] CrossRef
Significance of HPV16 Viral Load Testing in Anal Cancer
Ewa Małusecka, Ewa Chmielik, Rafał Suwiński, Monika Giglok, Dariusz Lange, Tomasz Rutkowski, Agnieszka M. Mazurek
Pathology & Oncology Research.2020; 26(4): 2191. CrossRef
Cervical cancer risk profiling: molecular biomarkers predicting the outcome of hrHPV infection
Mariano A Molina, Ludovica Carosi Diatricch, Marina Castany Quintana, Willem JG Melchers, Karolina M Andralojc
Expert Review of Molecular Diagnostics.2020; 20(11): 1099. CrossRef
MicroRNA-Based Fingerprinting of Cervical Lesions and Cancer
Justyna Pisarska, Katarzyna Baldy-Chudzik
Journal of Clinical Medicine.2020; 9(11): 3668. CrossRef

11,032 View
314 Download
23 Web of Science
23 Crossref

Omitting Adjuvant Radiotherapy for Hormone Receptor‒Positive Early-Stage Breast Cancer in Old Age: A Propensity Score Matched SEER Analysis: Yi-Jun Kim, Kyung Hwan Shin, Kyubo Kim; Cancer Res Treat. 2019;51(1):326-336. Published online May 10, 2018; DOI: https://doi.org/10.4143/crt.2018.163

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to investigate the non-inferiority of omitting radiotherapy (RT) after breast-conserving surgery (BCS) for hormone receptor (HR)‒positive T1N0 breast cancer in elderly women.
Materials and Methods
From 2004 to 2014, HR-positive T1N0 breast cancer patients aged 50 years or older and receiving BCS were retrieved from the Surveillance, Epidemiology, and End Results 18 database. After propensity score matching between the no-RT and RT groups, univariate and multivariate analyses were performed. Identified prognostic factors were used to stratify the risk groups. In each risk group, 10-year cancer-specific survival (CSS) rates were compared between the no-RT and RT groups.
Results
After propensity score matching, the numbers of patients in the no-RT and RT groups were both 18,586. For patients who satisfied both a tumor size of 1-10 mm and a tumor grade of 1-2, omitting RT did not decrease the CSS rate at any age group, ranging from ≥ 50 to ≥ 85 years; for patients aged ≥ 50 years, the 10-year CSS rates in the no-RT and RT groups were 97.2% and 96.8%, respectively (adjusted hazard ratio, 0.862; p=0.312). However, for patients with a tumor size of 11-20 mm or tumor grade of 3-4, RT significantly increased the CSS rate irrespective of age.
Conclusion
RT after BCS for HR-positive T1N0 breast cancer in elderly women might be omitted without causing a decrease in the CSS rate, but only in patients who satisfy both a small tumor size (≤ 10 mm) and low tumor grade (1-2).

Citations

Citations to this article as recorded by

Meta-Analysis of Different Surgical Methods for Breast Cancer Patients
Xiaoshu Zhao, Xunan Wei, Qing Shen, Xuanhong Zhou
International Journal of Pharmacology.2024; 20(5): 892. CrossRef
Radiotherapy is recommended for hormone receptor-negative older breast cancer patients after breast conserving surgery
Yaxiong Liu, Jinsong Li, Honghui Li, Gongyin Zhang, Changwang Li, Changlong Wei, Jinsheng Zeng
Scientific Reports.2024;[Epub] CrossRef
Comparison of breast‐conserving surgery without radiotherapy and mastectomy in the treatment of elderly patients with early breast cancer: A PSM and SEER database study
Baiyang Fu, Xi Chen, Wenlong Liang, Yao Wang, Yuan Yao, Jianguo Zhang
Cancer Medicine.2023; 12(14): 15229. CrossRef
Ways to improve breast cancer patients' management and clinical outcome: The 2020 Assisi Think Tank Meeting
Cynthia Aristei, Yasemin Bölükbaşı, Orit Kaidar-Person, Raphael Pfeffer, Meritxell Arenas, Liesbeth J. Boersma, Antonella Ciabattoni, Charlotte E. Coles, Pierfrancesco Franco, Marco Krengli, Maria Cristina Leonardi, Fabio Marazzi, Valeria Masiello, Icro M
Critical Reviews in Oncology/Hematology.2022; 177: 103774. CrossRef
Research on the cutoff tumor size of omitting radiotherapy for BCSS after breast conserving surgery in women aged 65 years or oder with low-risk invasive breast carcinoma: Results based on the SEER database
Zejian Yang, Kunlong Li, Pei Qiu, Yifei Ma, Bin Wang, Yu Yan, Du Meng, Chen Feng, Yu Ren, Yijun Li, Pingping Li, Can Zhou
The Breast.2021; 60: 287. CrossRef
Effectiveness of radiotherapy after breast-conserving surgery in older patients with T1-2N0 breast cancer
Anna Z. de Boer, Esther Bastiaannet, Nienke A. de Glas, Perla J. Marang-van de Mheen, Olaf M. Dekkers, Sabine Siesling, Linda de Munck, Kelly M. de Ligt, Johanneke E. A. Portielje, Gerrit Jan Liefers
Breast Cancer Research and Treatment.2019; 178(3): 637. CrossRef

10,430 View
297 Download
6 Web of Science
6 Crossref

Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma: Yongjun Cha, Yu Jung Kim, Se-Hoon Lee, Tae-Min Kim, Seung Hong Choi, Dong-Wan Kim, Chul-Kee Park, Il Han Kim, Jee Hyun Kim, Eunhee Kim, Byungse Choi, Chae-Yong Kim, In Ah Kim, Dae Seog Heo; Cancer Res Treat. 2017;49(1):129-140. Published online May 18, 2016; DOI: https://doi.org/10.4143/crt.2015.466

Abstract PDF PubReader ePub

Purpose
Bevacizumab±irinotecan is effective for treatment of recurrent malignant gliomas. However, the optimal duration of treatment has not been established.
Materials and Methods
Ninety-four consecutive patients with recurrent malignant glioma who were treated with bevacizumab at our institutions were identified. Patients who continued bevacizumab until tumor progression were enrolled in a late discontinuation (LD) group, while those who stopped bevacizumab before tumor progression were enrolled in an early discontinuation (ED) group. Landmark analyses were performed at weeks 9, 18, and 26 for comparison of patient survival between the two groups.
Results
Among 89 assessable patients, 62 (69.7%) and 27 (30.3%) patients were categorized as the LD and ED groups, respectively. According to landmark analysis, survival times from weeks 9, 18, and 26 were not significantly different between the two groups in the overall population. However, the LD group showed a trend toward increased survival compared to the ED group among responders. In the ED group, the median time from discontinuation to disease progression was 11.4 weeks, and none of the patients showed a definite rebound phenomenon. Similar median survival times after disease progression were observed between groups (14.4 weeks vs. 15.7 weeks, p=0.251). Of 83 patients, 38 (45.8%) received further therapy at progression, and those who received further therapy showed longer survival in both the LD and ED groups.
Conclusion
In recurrent malignant glioma, duration of bevacizumab was not associated with survival time in the overall population. However, ED of bevacizumab in responding patients might be associated with decreased survival.

Citations

Citations to this article as recorded by

The Vascular Microenvironment in Glioblastoma: A Comprehensive Review
Alejandra Mosteiro, Leire Pedrosa, Abel Ferrés, Diouldé Diao, Àngels Sierra, José Juan González
Biomedicines.2022; 10(6): 1285. CrossRef
Differential P-Glycoprotein/CD31 Expression as Markers of Vascular Co-Option in Primary Central Nervous System Tumors
Tiziana Annese, Mariella Errede, Antonio d’Amati, Michelina De Giorgis, Loredana Lorusso, Roberto Tamma, Domenico Ribatti
Diagnostics.2022; 12(12): 3120. CrossRef
Identification of diverse tumor endothelial cell populations in malignant glioma
Jeff C Carlson, Manuel Cantu Gutierrez, Brittney Lozzi, Emmet Huang-Hobbs, Williamson D Turner, Burak Tepe, Yiqun Zhang, Alexander M Herman, Ganesh Rao, Chad J Creighton, Joshua D Wythe, Benjamin Deneen
Neuro-Oncology.2021; 23(6): 932. CrossRef
Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy
Charlotte Bronnimann, Cristina Izquierdo, Stéphanie Cartalat, Laure Thomas, Bastien Joubert, Laura Delpech, Marc Barritault, David Meyronet, Jérôme Honnorat, François Ducray
Journal of Neuro-Oncology.2018; 138(1): 141. CrossRef

10,682 View
181 Download
5 Web of Science
4 Crossref

Case Report

A Rare Presentation of Follicular Lymphoma: Cerebellar Involvement, Successfully Treated with a Combination of Radiotherapy and Chemotherapy: Nuri Karadurmus, Selmin Ataergin, Gokhan Erdem, Mustafa Cakar, Ozdes Emer, Sukru Ozaydin, Mustafa Ozturk, Mukerrem Safali, Fikret Arpaci; Cancer Res Treat. 2013;45(3):234-238. Published online September 30, 2013; DOI: https://doi.org/10.4143/crt.2013.45.3.234

Abstract PDF PubReader ePub

The central nervous system (CNS) is an important area of involvement for both high-grade, aggressive primary and secondary lymphomas. Although follicular lymphoma represents a low-grade histology, it may rarely present with CNS involvement. Here, we describe a patient diagnosed with follicular lymphoma who was presented with cerebellar involvement.

Citations

Citations to this article as recorded by

Follicular lymphoma with secondary central nervous system relapse: a case report and literature review
Yuri Tsuboi, Misayo Shimizu, Akihiro Kuroda, Takuya Suyama, Masanori Seki, Atsushi Shinagawa
Oxford Medical Case Reports.2023;[Epub] CrossRef
Rare central nervous system lymphomas
Furqaan Ahmed Kaji, Nicolás Martinez‐Calle, Vishakha Sovani, Christopher Paul Fox
British Journal of Haematology.2022; 197(6): 662. CrossRef
Secondary parenchymal CNS involvement by lymphoma including rare types: Follicular and EBV-positive NK/T cell lymphoma, nasal type
B.K. Kleinschmidt-DeMasters, Ahmed Gilani
Annals of Diagnostic Pathology.2021; 53: 151765. CrossRef
Cerebral Amyloidoma Resulting from Central Nervous System Lymphoplasmacytic Lymphoma: A Case Report and Literature Review
Geetha Jagannathan, Guldeep Uppal, Kevin Judy, Mark T. Curtis
Case Reports in Pathology.2018; 2018: 1. CrossRef
Sites of extranodal involvement are prognostic in patients with stage 1 follicular lymphoma
Aditi Shastri, Murali Janakiram, Ioannis Mantzaris, Yiting Yu, Jaime S. Londono, Amit K. Verma, Stefan K. Barta
Oncotarget.2017; 8(45): 78410. CrossRef
Follicular Lymphoma Presenting with Leptomeningeal Disease
Rubens Costa, Ricardo Costa, Renata Costa
Case Reports in Hematology.2014; 2014: 1. CrossRef

12,363 View
100 Download
6 Crossref

Original Articles

Prognostic Factors of Gastrointestinal Leiomyosarcoma in Korea: Se Hoon Lee, Hee Jeoung Cha, Jee Hyun Kim, Im Il Na, Jun Hee Lee, Hark Kyun Kim, Keun Seok Lee, Won Sup Lee, Chong Jai Kim, Dae Seog Heo, Yung Jue Bang, Noe Kyeong Kim; J Korean Cancer Assoc. 2000;32(6):1022-1030.

Abstract PDF: PURPOSE
The clinicopathologic features and prognostic factors of gastrointestinal leiomyosarcoma have been a source of controversy.
MATERIALS AND METHODS
A retrospective study was made of 91 incident cases of gastrointestinal leiomyosarcoma from 1979 to 1998 to identify clinicopathologic features and prognostic factors.
RESULTS
The median age of study subjects was 56 years and 58.2% was male. Tumors consisted of 2 esophagus, 39 stomach, 38 small bowel, 12 large bowel leiomyosarcoma. Mean size of the tumors was 10.9 cm and 52.9% of them was larger than 10 cm. The tumors were classified as localized stage (42 cases), advanced stage (21 cases), and metastatic stage (28 cases). Again, the tumors were classified as low grade (48 cases) and high grade (18 cases). Median overall survival was 37.4 months and median disease-free survival was 28.2 months. In univariate analysis, the significant factors affecting the overall survival of patients with leiomyosarcoma were stage, size greater than 10 cm, performance status, and histologic grade. In multivariate analysis, stage, performance status, and histologic grade were independent factors affecting the overall survival. In univariate analysis, the significant factors affecting the disease-free survival were stage, performance status, and histologic grade. In multivariate analysis, histologic grade was the only independent factor affecting the disease-free survival.
CONCLUSION
Stage, performance status, and histologic grade were independent factors affecting the overall survival. Histologic grade was independent factor affecting the disease-free survival.

2,893 View
14 Download

Comparison of Rb and p53 Protein Expression with Stage and Grade as a Prognostic Value in Renal Cell Carcinoma: Hye Jeong Choi, Mi Jin Ko, Mi Jin Kim, Dong Sug Kim; J Korean Cancer Assoc. 1999;31(5):979-985.

Abstract PDF: PURPOSE
This study was performed to evaluate prognostic significance of Rb and p53 protein immunostaining in renal cell carcinoma. We investigated correlations between Rb, p53 immunostaining and nuclear grade and stage as prognostic factors of renal cell carcinoma.
MATERIALS AND METHODS
Subjects of this study were sixty-nine cases of renal cell carcinoma. We used indirect immunohistochemical methods in the formalin-fixed paraffin- embedded tissue (Rb: Pharmingen, USA; p53: Novocastra, UK). In staging and nuclear grading of the renal cell carcinoma, the American Joint Commitee on Cancer (AJCC) TNM system and Fuhrmans grading system were applied respectively.
RESULTS
According to Fuhrmans grading system, four cases were classified grade I, 15 cases were classified grade II, 13 cases were classified grade III, and 37 cases were classified grade IV. By AJCC TNM staging system, 29 cases were grouped stage I, 20 cases were grouped stage II, 15 cases were grouped stage III and five cases were grouped stage IV. In 55 cases (79% of all cases), Rb protein was expressed. Expression of Rb protein did not correlate with nuclear grade nor tumor stage. p53 protein was expressed in 17 cases (24% of all cases). p53 protein expression was frequently detected in high nuclear grade group (p < 0.05), but was not correlated with tumor stage.
CONCLUSION
Expression of Rb protein was not conelated with nuclear grade and stage. And expression of p53 protein was not correlated with stage, but it is correlated with nuclear grade. Thus immunohistochemical examinstion of p53 could be a histological prognostic factor.

2,921 View
17 Download

Study on the Expression of E-cadherin and Cathepsin B in the Prostatic Carcinomas with the Evaluation of the Gleason Grade: Mee Young Sol, Jin Sook Lee, Hyo Jeong Chae, Moon Kee Chung; J Korean Cancer Assoc. 1998;30(5):980-989.

Abstract PDF: PURPOSE
The purpose of this study is to evaluate the expression of E-cadherin and cathepsin-B in prostatic carcinomas and correlate with the Gleason grades.
MATERIALS AND METHODS
The expressions of E-cadherin and cathepsin B were examined by the immunohistochemical technic using the antibodies against the E-cadherin and cathepsin B on the paraffin block sections of 56 prostatic carcinomas with evaluation of Gleason grading.
RESULTS
E-cadherin expression in normal epithelium was membranous intercellular expression and those of prostate carcinomas were aberrant expressions such as negative expression or cytoplasmic presentation. The expressivity of the E-cadherin according to the progression of the Gleason grading revealed negative membranous expression and tendency of gradual increase of aberrant expression. The normal prostate and BPH revealed expression of cathepsin B mostly in the basal layers of acini as cytoplasmic reaction and the stromal macrophages and microvessel wall also showed positive expression. The prostatic carcinoma showed cytoplasmic positivity in the cancer cells and the expression rate was increased from Gleason grade 2 to Gleason grade 4. But the Gleason grade 5 tissue revealed decreased or negative expression. The Gleason grade 4, especially in the invasive cells and invasive edges, revealed the most intense and frequent expression of cathepsin B and this findings were consistent with the nonnal function of the cathepsin B as a protease degrading the extracellular matrix proteins.
CONCLUSION
E-cadherin expression was aberrant after Gleason grade 6 related with high histologic grades. It is suggested that the E-cadherin expression could tell the potential cancer progression as a tumor suppression factor. The cathepsin B was most strongly expressed in basal cells of the benign prostatic acini and the cancer nests of Gleason grade 4, which tells the possibility that cathepsin B could be a marker of basocellular differentiation and of assessing stromal invasion of prostatic carcinomas.

2,549 View
16 Download

Clinicopathologic Comparison of Intermediate or High Grade Peripheral T-Cell Lymphoma with Diffuse B-Cell Lymphoma: Kyung Hae Jung, In Sook Woo, Heung Moon Chang, Dae Seog Heo, Yung Jue Bang, Chul Woo Kim, Seonyang Park, Byoung Kook Kim, Noe Kyeong Kim; J Korean Cancer Assoc. 1997;29(1):136-145.

Abstract PDF: PURPOSE
Peripheral T-cell lymphoma (PTCL) derived from mature T cells forms morphologically diverse group of non-Hodgkin's lymphomas and the clinicopathologic features remain to be debated. In order to elucidate the specific characteristics of PTCL, comparison with a group of diffuse B-cell lymphomas (DBCL) was done.
MATERIALS AND METHODS
Between Dec. 1989 and Feb. 1993, clinical data of 67 cases of intermediate or high grade NHL identified as T-cell or B-cell origin by immunophenotyping was reviewed.
RESULTS
There were 30 cases of PTCL and 37 cases of DBCL. PTCL had more advanced stage and B symptoms at diagnosis. Frequent sites of extranodal involvement were bone marrow, nasal cavity/paranasal sinus, and skin in PTCL and gastrointestinal tract in DBCL. Based on NCI Working Formulation, 40% of PTCL and 14% of DBCL were high grade. Patients with DBCL had a better 3-year overall survival rate (67% vs 47%), however, there was no difference in complete remission rate and disease-free survival rate between two groups with intensive treatment. A subgroup of PTCL patients who had died earlier was found to have more advanced stage and poor performance status.
CONCLUSION
Although patients with PTCL had worse survival in advanced stage, the outcome of patients with PTCL who received intensive treatment was comparable to that of DBCL.

2,525 View
12 Download

Correlation of Tumor Grade and other prognostic factors in Invasive Breast Carcinoma: Young Bae Kim, Tae Sook Hwang, Joon Mee Kim, Young Chae Chu, Kyung Ja Cho, Ja June Jang; J Korean Cancer Assoc. 1994;26(6):926-936.

Abstract PDF: The prognostic factors in breast cancer are tumor stage, type, grade, hormonal receptor, tumor proliferative fraction, oncogene, altered growth factor receptor and angiogenesis. Since the first systematic study on grading system of breast cancer was published by Greenhough in 1925, a number of grading systems including Bloom-Richardson's histologic method and Blacks nuclear method have been reported and used. These grading systems have been considered as a classic and important prognostic factor for long time. In spite of this fact, there is a growing tendency that pathologists and clinicians disagree with grading system due to different results for prognosis and lack of reproducibility. Although these earlier analyses indicated that Bloom-Richardsons grade is prognostically more significant than Blacks grade, subsequent analysis indicate the converse. To investigate and evaluate usefulness of Bloom-Richardson grade and Black's grade, we examined the correlation of two grading systems and other estabiished prognostic factors, (i.e, tumor size, status of estrogen receptor, c-erbB-2 oncoprotein, Ki-67 labelling index, axillary nodal metastasis and microvessel count), in 62 cases of infiltrative ductal carcinoma of the breast. 1) Bloom-Richardson's histologic grade had significant correlation in nuclear grade, status of estrogen receptor, and Ki 67 labelling index. Tumor size and c-erbB-2 oncoprotein were also correlated with histologic grade, but it was statistically insignificant. 2) Blacks nuclear grade had also significant correlation in histologic grade, status of estro- gen receptor, c-erbB-2 oncoprotein and Ki 67 labelling index. Tumor size and axillary node metastasis were correlated, but they were statistically insignificant. 3) Metastasis and angiogenesis were not correlated with tumor grade. We could not compare histologic grade with nuclear grade fundamentally, because we failed to pursue patient's survival rate. However tumor grade in breast carcinoma served as a mandatory factor to get insights for status of other established prognostic factors or further prediction of patient's prognosis.

3,161 View
29 Download

First
Prev
Page of 1
Next
Last

Search